Rachel Ellingson

Rachel Ellingson (senior executive) discloses dealings in 2 companies, chiefly Biolife Solutions Inc and Zimmer Biomet Holdings, Inc. Between 1 May 2021 and 6 October 2026, the trades on record add up to 18 filings.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.

The latest filing, published on 8 October 2026, reports a transaction in Biolife Solutions Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.